Overview

* Kodiak Sciences ( KOD ) reports Q3 net loss of $61.5 mln, increased from $43.9 mln last year

* R&D expenses rise to $50.5 mln in Q3, driven by active clinical studies

* Kodiak ends Q3 with $72 mln in cash, down from $168 mln last year

Outlook

* Kodiak expects topline data for tarcocimab's Phase 3 GLOW2 study in 1Q 2026

* Topline data for KSI-501's Phase 3 DAYBREAK study expected in 3Q 2026

* Kodiak anticipates topline data for KSI-101's Phase 3 PEAK study in 4Q 2026

Result Drivers

* CLINICAL STUDY PROGRESS - Increased R&D expenses driven by active DAYBREAK and PEAK/PINNACLE studies and manufacturing activities

* RAPID ENROLLMENT - Phase 3 PEAK and PINNACLE studies of KSI-101 enrolling faster than expected

* MECHANISM VALIDATION - KSI-101 mechanism of action validated by scientific community, enhancing clinical effect

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$1.16

Q3 Net -$61.46

Income mln

Q3 Basic -$1.16

EPS

Q3 $62.35

Operatin mln

g

Expenses

Q3 -$62.35

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Kodiak Sciences Inc ( KOD ) is $17.00, about 19.1% below its November 12 closing price of $20.25

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)